Vera Therapeutics (VERA) Total Liabilities (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Total Liabilities data on file, last reported at $122.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 62.36% year-over-year to $122.0 million; the trailing twelve-month figure through Mar 2026 stood at $122.0 million (up 62.36% YoY), and the FY2025 full-year result was $130.2 million, up 65.82% from the prior year.
• Total Liabilities for Q1 2026 stood at $122.0 million, down from $130.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $130.2 million in Q4 2025 and bottomed at $25.7 million in Q3 2022.
• The 5-year median for Total Liabilities is $69.4 million (2024), against an average of $71.8 million.
• The widest annual swing landed in 2022, when Total Liabilities jumped 448.95%; it then increased 6.32% in 2024.
• A 5-year view of Total Liabilities shows it stood at $54.5 million in 2022, then surged by 35.46% to $73.9 million in 2023, then climbed by 6.32% to $78.5 million in 2024, then jumped by 65.82% to $130.2 million in 2025, then retreated by 6.27% to $122.0 million in 2026.
• The last three Total Liabilities figures came in at $122.0 million (Q1 2026), $130.2 million (Q4 2025), and $118.6 million (Q3 2025), per Business Quant data.

Peer Comparison